Axsome Malta Patent-Cliff Exposure & CMS Drug Spending Portfolio

Axsome Malta (US): 1 reconciled FDA prescription therapies, $33.9M 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2042-01-01
2024 CMS Total Public Spend$33.9M
2024 Medicare Part D Spend$21.0M
2024 Medicaid Spend$12.9M
California HCAI SB 17 Filings10 WAC filings (max 24.7% 2-yr change)